06/23/22 4:00 PMNasdaq : ANEB clinical triallow floatAnebulo Pharmaceuticals to Announce Topline Data for ANEB-001 from an Ongoing Phase 2 Clinical Trial for Acute Cannabinoid Intoxication on Tuesday July 5, 2022Anebulo Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse disorder, anticipates releasing topline data from Part A of its ongoing Phase 2 study of ANEB-001 on July 5th. Anebulo Pharmaceuticals, Inc. is a clinical-stage...RHEA-AIneutral
05/24/22 4:00 PMNasdaq : ANEB managementlow floatAnebulo Pharmaceuticals Appoints Kenneth Cundy, Ph.D., as Chief Scientific OfficerAnebulo Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse disorder, today announced the appointment of Dr. Dr. Cundy is a highly respected scientist having innovated and developed multiple therapeutics throughout his career.RHEA-AIpositive
05/11/22 9:00 AMNasdaq : ANEB earningslow floatAnebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2022 Financial Results and Recent UpdatesAnebulo Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse, today announced financial results for the three months ended March 31, 2022 and recent updates. Completed enrollment of all 60 subjects in Part A of an ongoing Phase 2...RHEA-AIneutral
04/01/22 7:00 AMNasdaq : ANEB clinical triallow floatAnebulo Pharmaceuticals Doses More Than Half of the Subjects in Part A of a Phase 2 Clinical Trial and Provides Guidance on IND SubmissionAnebulo Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse disorder, today announced the dosing of more than half of the 60 subjects planned in Part A of an ongoing Phase 2 clinical trial at the Centre for Human Drug Research in the...RHEA-AIneutral
02/11/22 8:00 AMNasdaq, NYSE : ANEB, AMAM, OIIM earningslow floatAnebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2022 Financial Results and Recent UpdatesAnebulo Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse, today announced financial results for the three months ended December 31, 2021 and recent updates. Mr. Allen started his career in the lab at Gilead Sciences working on...RHEA-AIneutral
01/06/22 7:00 AMNasdaq : ANEB conferenceslow floatAnebulo Pharmaceuticals to Present at the H.C. Wainwright BioConnect Virtual ConferenceAnebulo Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse, announces that management will present a company overview at the H.C. Wainwright BioConnect Virtual Conference being held January 10-13, 2022. Anebulo Pharmaceuticals,...RHEA-AIneutral
01/06/22 7:00 AMNasdaq : ANEB managementlow floatAnebulo Pharmaceuticals Appoints Scott L. Anderson as Head of Investor Relations and Public RelationsAnebulo Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse, announced today that it has appointed Scott L. Anderson as Head of Investor Relations and Public Relations, effective immediately. In this position, Mr. Anderson will report...RHEA-AIneutral
01/04/22 7:00 AMNasdaq, NYSE : ANEB, AMAM low floatAnebulo Pharmaceuticals Names Biotechnology Industry Executive Simon Allen as CEO and DirectorAnebulo Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse, has named Simon Allen as Chief Executive Officer and a member of the company’ s Board of Directors, effective February 1 st, 2022. Mr. Allen succeeds Daniel Schneeberger, MD, who...RHEA-AIpositive
01/03/22 7:00 AMNasdaq : ANEB clinical triallow floatAnebulo Pharmaceuticals Announces Initiation of Phase 2 Clinical Study Evaluating ANEB-001 for the Treatment of Acute Cannabinoid IntoxicationAnebulo Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse, announces that the first patient has been dosed in a Phase 2 proof-of-concept clinical study investigating ANEB-001 as a potential treatment for acute cannabinoid...RHEA-AIneutral
12/22/21 4:05 PMNasdaq : TNYA, EOLS, ANEB managementlow floatTenaya Therapeutics Appoints Karah Parschauer, J.D., to Its Board of Directors and Joanna Auch as Senior Vice President of People and CultureTenaya Therapeutics, Inc., a biotechnology company with a mission to discover, develop and deliver curative therapies that address the underlying causes of heart disease, today announced the appointments of Karah Parschauer, J.D., to its Board of Directors and of Joanna Auch as Senior Vice President of People and Culture. Her previous experience includes over...RHEA-AIneutral